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Dominant Effects of D40p53 on p53 Function and
Melanoma Cell Fate
Rie Takahashi1,2,3, Svetomir N. Markovic4,5,6 and Heidi J. Scrable2,3,7
The TP53 gene encodes 12 distinct isoforms, some of which can alter p53 activity in the absence of genomic
alteration. Endogenous p53 isoforms have been identified in cancers; however, the function of these isoforms
remains unclear. In melanoma, the frequency of TP53 mutations is relatively low compared with other cancers,
suggesting that these isoforms may have a larger role in regulating TP53 activity. We hypothesized that p53
function and therefore cell fate might be altered by the presence of D40p53, an embryonic isoform missing the
first 40 N-terminal amino acids of the full-length protein including the transactivation and Mdm2-binding
domains. To test this hypothesis, we transduced tumor and normal cells with a lentivirus encoding D40p53. We
found that exogenous D40p53 caused apoptosis and increased the levels of endogenous, activated p53 in both
cancerous and non-cancerous cells, which led to significant levels of cell death, particularly in cancer cells.
Activated p53 molecules formed nuclear heterotetramers with D40p53 and altered downstream p53 transcription
target levels including p53-induced protein with death domain and cyclin-dependent kinase inhibitor, p21.
D40p53 altered the promoter occupancy of these downstream p53 target genes in such a way that it shifted cell
fate toward apoptosis and away from cell cycle arrest. We show that tumor suppression by p53 can occur via an
alternate route that relies on its interaction with D40p53.
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INTRODUCTION
To understand the initiation and progression of cancers, numer-
ous tumor suppressors have been screened for the presence of
mutations and changes in protein expression (Machado-Silva
et al., 2010; Robles and Harris, 2010; Cheok et al., 2011).
TP53 has been shown to orchestrate an appropriate tumor
suppressor function by trans-activating or -suppressing cell cycle
and apoptosis genes in response to a particular dose and quality
of cellular stress (Vousden and Prives, 2009; Beckerman and
Prives, 2010; Belyi et al., 2010; Lane and Levine, 2010).
The importance of proper p53 function is emphasized by its
high mutation frequency among human cancers (Hollstein
et al., 1991; Levine et al., 1991; Petitjean et al., 2007)
and the overexpression of ‘mutant’ p53 in certain tumors
suggests that some mutations may have a dominant-negative
effect on wild-type p53 (Oren and Rotter, 2010; Goldstein
et al., 2011). Certain cancers such as melanomas harbor
wild-type TP53; however, these tumors bypass the regulatory
functions of p53 and continue to proliferate and meta-
stasize (Albino et al., 1994; Montano et al., 1994; Weiss
et al., 1995; Zerp et al., 1999; Soto et al., 2005; Gwosdz
et al., 2006; Li et al., 2006). This poses the question of how
melanoma cells continue to proliferate in the presence of wild-
type TP53.
The TP53 gene encodes 12 protein isoforms that are missing
specific regions of full-length p53 (Marcel et al., 2011) and
are capable of altering the p53 function (Courtois et al., 2002;
Ghosh et al., 2004; Khoury and Bourdon, 2010). Specific p53
isoforms have been identified in both cancer (Bourdon et al.,
2005b; Anensen et al., 2006; Boldrup et al., 2007; Avery-
Kiejda et al., 2008; Marcel et al., 2010; Takahashi et al., 2012)
and non-cancerous tissues (Ungewitter and Scrable, 2010b).
One of these isoforms, D40p53, is missing the first 40 amino
acids encoding the first transactivation domain and can be
synthesized primarily by alternative translation initiation in
exon 4 (Courtois et al., 2002; Yin et al., 2002; Grover et al.,
2008, 2009, 2011) and by alternative splicing of intron 2
(Ghosh et al., 2004). D40p53 is uniquely expressed during
early embryogenesis (Maier et al., 2004a; Ungewitter and
Scrable, 2010b), is associated with less differentiated, proli-
ferative cells, and cannot be found in corresponding adult
tissues (Maier et al., 2004a; Medrano et al., 2009b; Takahashi
et al., 2012). The overall frequency of D40p53 protein
expression in cancer, including melanoma, remains
unknown.
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We previously showed that D40p53 is highly and consis-
tently expressed at the protein level in both glioblastoma
and gliosis tissues but not in normal brain cortex (Takahashi
et al., 2012). Given that D40p53 is uniquely found in stem
cell populations, the discovery of its endogenous expression
in glioblastoma tumors raises the question of whether this
isoform profile reflects a subpopulation of less differen-
tiated, proliferative cells within a tumor or an attempt by the
host to activate p53 and curb tumor growth. To distinguish
between these possibilities, we generated a lentiviral vector
that could deliver D40p53 to melanoma cells with high
efficiency. We hypothesized that if high expression of
D40p53 were associated with proliferative, less differen-
tiated cell types, then transduced cells would take on the
growth characteristics of rapidly dividing cells, resulting in
increased cell number. Alternatively, if higher than normal
expression of D40p53 reflected an attempt by the cells to slow
down proliferation, then transduced cells would be expected
to exhibit characteristics of tumor suppression, such as
increased apoptosis or cell cycle arrest, resulting in reduced
numbers of cells. We asked if D40p53 could reactivate
endogenous p53 function in melanoma cells to favor tumor
suppression. Our results are consistent with a model where
p53 activation can occur via an alternate route that relies on
its interaction with D40p53 to modify downstream targets and
promote cell death over cell cycle arrest.
RESULTS
Excess D40p53 increases the fraction of dead cells in cultures
of tumor and normal cells
We used a lentivirus encoding D40p53 (D40p53V) driven by
the spleen focus-forming virus promoter (Figure 1a) to over-
express D40p53 in four different cell types: A375 melanoma
cells, primary glioblastoma xenograft cells, human melano-
cytes, and mouse embryonic fibroblasts (Figure 1b). A pre-
viously described lentivirus encoding green fluorescence
protein (GFP) (EV; Figure 1a) or no infection (NI) was used
as controls (Demaison et al., 2002). We achieved transduction
efficiencies of 495% as determined by the expression of a
GFP reporter included in both the empty vector (EV) and the
D40p53-encoding lentivirus (Figure 1a and Supplementary
Figure S1 online). Using a panel of p53 antibodies that bind
specific domains of the p53 protein (Figure 1c), which we
previously developed to detect full-length p53 and its isoforms
(Takahashi et al., 2012), we demonstrated that exogenous
D40p53 was expressed in transduced cells (Figure 1d). P53
antibodies HR231 and CM1 detected D40p53 in A375 mela-
noma cells transduced with D40p53V, but not in uninfected
cells (NI) or cells transduced with the EV. The N-terminal
antibody DO1 detected endogenous p53 expression, but only
in D40p53V-transduced cells. HR231 also detected endo-
genous p53 upon higher exposure (data not shown). Approxi-
mately 5 days after infection, there were fewer adherent A375
melanoma and primary glioblastoma cells in wells treated
with D40p53 lentivirus compared with controls (Figure 1b, top
two panels). To determine if this was due to decreased
proliferation or increased cell death, we incubated A375
melanoma cells with ethidium homodimer, a DNA-binding
molecule that is impermeable to cells with intact cell
membranes. The relative number of dead cells was signifi-
cantly increased in D40p53-infected cultures compared with
EV controls (Figure 1e). Using trypan blue exclusion, we did
not find a significant difference in the number of viable cells
between D40p53-infected cells and controls (data not shown).
We also found decreased numbers of adherent cells in
melanocytes and mouse embryonic fibroblasts, but at 10 days
rather than 5 days after infection (Figure 1b, bottom two
panels). Thus, D40p53 did appear to affect the growth of
cultures of both tumor and normal cells by decreasing cell
viability.
D40p53 causes apoptosis
p53 activates pathways that can result in cell cycle arrest or
apoptosis in response to different cellular stressors and
damage. To determine if the visible decrease in viable cells
in the presence of increased D40p53 expression was due to
apoptosis or to prolonged cell cycle arrest, we analyzed
apoptosis and membrane integrity in D40p53-infected cells
with PE–conjugated Annexin V and a DNA-binding dye,
7-aminoactinomycin D, respectively (Figure 2a, middle row).
We found an approximately 3-fold increase in double-positive
(late apoptotic) cells, a 2.7-fold increase in Annexin V single–
positive (early apoptotic) cells, and a 4.5-fold increase in total
Annexin V–positive cells with D40p53 infection compared
with controls. Consistent with the apoptosis results, we
observed a 4.4-fold increase in the proportion of subdiploid
cells in D40p53-infected cultures compared with controls, as
determined by propidium iodide staining and flow cytometric
analysis (Figure 2a, bottom row). We found a similar increase
in apoptosis in primary glioblastoma xenograft cells infected
with D40p53 (Supplementary Figure S2 online). We further
confirmed our findings with western blot analysis using
antibodies that detect cleaved or full length poly-(ADP-
ribose)-polymerase I (PARP I), a caspase target that is cleaved
during the late phase of apoptosis (Oliver et al., 1998). As
shown in Figure 2b, we found an increase in cleaved PARP I
product in D40p53-infected lysates, a 2.2-fold increase rela-
tive to full-length PARP I, compared with 0.5-fold in both NI
and EV controls. We carried out similar experiments in p53-
deficient cells and did not observe an increase in the
proportion of apoptotic cells in D40p53-infected cells com-
pared with EV controls (Supplementary Figure S3 online).
These results indicate that D40p53 reduces cell viability
by inducing apoptosis, but only in cells that express full-
length p53.
D40p53 does not cause cell cycle arrest
To determine if D40p53 affected cell cycle progression, we
infected A375 melanoma cells with D40p53 or EV and ana-
lyzed the cells by flow cytometry in the presence of propidium
iodide. Consistent with our apoptosis results (Figure 2a and b),
we observed a 4.5-fold increase in the percentage of sub-
diploid cells infected with the D40p53 lentivirus (Figure 2c,
top row). However, we did not find significant differences in
the cell cycle distributions of cycling D40p53- and EV-infected
or NI A375 cells (Figure 2d, unshaded area).
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Next, we induced cell cycle arrest and determined cell
cycle profiles at 0, 3, 6, and 9 hours following 7 Gy of g-
irradiation. Representative plots and quantitation at the 3-hour
time point are shown in Figure 2c (bottom row) and Figure 2d
(shaded area), respectively. We did not find differences in
cell cycle profiles with D40p53 compared with EV controls
at any timepoints. By 9 hours after irradiation, we observed
a decrease in the percentage of S-phase cells across all condi-
tions, indicating that both infected and uninfected cells were
able to respond to g-irradiation (data not shown). We obtained
similar results in normal melanocytes, where the cell cycle
distributions were the same with or without g-irradiation and
in both infected and NI cells (Supplementary Figure S4
online). We also did not find an increase in the percentage
of subdiploid cells in g-irradiated samples compared with non-
irradiated samples (Figure 2d, % subdiploid). Collectively,
these results suggested that D40p53 might selectively affect
cell death while leaving cell cycle arrest unchanged.
One of the canonical pathways of tumor suppression by p53
involves ATM/ATR (ataxia telangiectasia mutated/ATM- and
Rad3-related) phosphorylation of p53 at serine 15 by ionizing
radiation (Siliciano et al., 1997; Banin et al., 1998; Canman
et al., 1998; Khanna et al., 1998). The choice between cell
cycle arrest and apoptosis is affected by the level of p53 and
post-translational modifications at residues such as serine 15
(Vousden and Prives, 2009; Hollstein and Hainaut, 2010). We
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compared the level of serine 15 phosphorylation in NI cells to
cells infected with D40p53V or EV by western blot analysis at
0, 3, 6, and 9 hours after irradiation (Figure 2e, ser 15).
Exogenous D40p53 expression was confirmed using antibo-
dies HR231, CM1, and pAb1801 (Figure 2e, bottom panels).
We found that serine 15 phosphorylation was increased in
cells infected with D40p53V even in the absence of ionizing
radiation (Figure 2e, 0 hours). Serine 15 phosphorylation was
increased as early as 3 hours and sustained to 9 hours
after irradiation in both uninfected and infected cells, but
to significantly higher levels in D40p53-expressing cells
(Figure 2e, ser 15). Total full-length p53 as detected by DO1
was similarly affected (Figure 2e, DO1). Although there were
increased levels of phospho-p53 in D40p53-expressing cells
compared with EV control, there was no significant difference
within each group over time (Supplementary Figure S5
online). We observed similar effects of D40p53 and g-irradia-
tion in a second melanoma cell line (WM266) and in human
melanocytes (Supplementary Figure S6 online). These results
suggested that D40p53 enhanced the activation of p53 in
response to genotoxic stress through ATM/ATR–dependent
phosphorylation of serine 15.
Given that p53 can be activated by g-irradiation through the
canonical ATM/ATR-serine15 phosphorylation pathway, we
hypothesized that, D40p53, similar to g-irradiation, might act
through ATM/ATR to increase serine 15–phosphorylated p53
levels. To test the dependence of serine 15 phosphorylation on
the activity of the ATM/ATR pathway, we again infected cells
with D40p53V, but this time in the presence of CGK733, an
ATM/ATR inhibitor (Crescenzi et al., 2008; Bhattacharya et al.,
2009). Inhibition of ATM/ATR kinase activity prevented serine
15 phosphorylation in EV and NI controls, but had no effect
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on the level of serine 15 phosphorylation in D40p53-
transduced cells (Figure 3a). This suggests that D40p53V acts
through a mechanism that is different from that of ATM/ATR
activation seen with g-irradiation. We also compared the
levels of other kinases and phosphatases known to affect
serine 15 phosphorylation, but did not find any significant
changes that could account for the increased phosphorylation
seen in D40p53-infected cells (Figure 3b). What we did find,
however, was a strong, D40p53-dependent increase in serine
15 phosphorylation under conditions that induce ER stress and
the unfolded protein response (Ito et al., 2006; Shenkman
et al., 2007). As shown in Figure 3c, blocking protein trans-
lation with cycloheximide led to a gradual increase in the
level of serine 15–phosphorylated p53 concurrent with the
decline of control proteins, such as cyclin B1, and virally
encoded D40p53 (Figure 3c, CM5). Taken together with
previous results, these data suggest that activation of p53 by
D40p53, which is reflected in the phosphorylation of serine
15, is primarily in response to proteotoxic rather than
genotoxic stress brought on by high levels of D40p53 relative
to full-length p53.
D40p53 increases the expression of apoptotic gene, PIDD, and
suppresses expression of cell cycle arrest gene, p21
p53 exerts its tumor suppressor activity and cellular response
to damage primarily as a transcription factor. We therefore
asked if the presence of excess D40p53 might alter the levels
of p53 transcription target gene expression. To discover
candidate p53 targets altered by the introduction of D40p53,
we used a PCR array containing 84 known p53 targets to
compare fold changes in D40p53-transduced cells relative to
EV–infected cells (Supplementary Figure S7A online, upper
panel 0 Gy). When comparing D40p53V samples to EV,
we found that the majority of transcript levels relative to EV
were within a 3-fold dynamic range based on a log10 scale
(Figure 4a, black circles). However, there were eight target
genes outside this dynamic range (Figure 4a, red circles),
and five of these are involved in apoptosis (Supplementary
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Figure 3. D40p53 activates p53 under proteotoxic, but not genotoxic, conditions. (a) Serine 15 (ser15)–phosphorylated p53 in A375 cells infected with empty
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Figure S7B online). On the basis of these data, we focused on
the expression of individual genes involved in apoptosis (PIDD
(p53-induced protein with death domain), PCBP4, APAF1, and
Bax) and on two cell cycle arrest genes (p21 and GADD45),
which exhibited reduced expression in the array. Single gene
transcript levels determined by quantitative reverse transcriptase
in real time revealed an increase in the apoptotic gene, PIDD,
in D40p53 infected cells compared with EV controls (Figure 4b).
These data were consistent with the increased apoptosis
observed in the presence of D40p53V (Figure 2a and b).
Next, we screened 84 known p53 targets by PCR array
3 hours after exposure to 7 Gy g-irradiation in A375 melanoma
cells infected with D40p53V or EV (Supplementary Figure S7A
online, bottom panel 7 Gy). Changes in p21 and PIDD were
verified by single-gene quantitative reverse transcriptase in
real time (Figure 4c).
D40p53 oligomerizes with endogenous activated p53 in the
nucleus
To determine the mechanism by which D40p53 could alter
p53 target gene expression and increase apoptosis, we first
asked if both activated p53 and D40p53 localized to the
nucleus. We fractionated D40p53V or EV-infected A375
melanoma cells and determined the subcellular localization
of D40p53 and full-length p53 by western blot analysis
(Figure 5a). D40p53, serine 15–phosphorylated p53, and total
full-length p53 were exclusively found in the nucleus. The
small amount of endogenous p53 detected in the cytoplasmic
4
*
EV 0Gy
Δ40p53V 0Gy
Δ4
0p
53
 lo
g 1
02
–
ΔC
t
Empty vector log102–ΔCt
PIDD PCBP4
*
3
2
1
PID
D
PC
BP
4
AP
AF
1
GA
DD
45
A
Ba
x
p2
1
EV
EV
 (7G
y)
Δ4
0p
53
V
Δ4
0p
53
V (7
Gy) EV
EV
 (7G
y)
Δ4
0p
53
V
Δ4
0p
53
V (7
Gy)
EV
EV
 (7G
y)
Δ4
0p
53
V
Δ4
0p
53
V (7
Gy)EV
EV
 (7G
y)
Δ4
0p
53
V
Δ4
0p
53
V (7
Gy)
R
el
at
iv
e 
to
 N
I
0
4
3
2
1R
el
at
iv
e 
to
 N
I
R
el
at
iv
e 
to
 N
I
R
el
at
iv
e 
to
 N
I
0
4
3
2
1R
el
at
iv
e 
to
 N
I
0
8
GADDD45A
6
4
2
0
1.5
p21
*
1.0
0.5
0.0
1.26
0.26
–0.74
–1.74
–2.74
–3.74
–4.74 –3.74 –2.74 –1.74 –0.74 0.26 1.26
Figure 4. D40p53 increases the expression of apoptotic gene, PIDD, and suppresses expression of cell cycle arrest gene, p21. (a) Potential p53 gene targets
altered by D40p53V. Log-scale dot plot of gene target levels in D40p53V versus empty vector (EV). Eight genes (red circles) fell outside of the 3-fold dynamic
range (delineated by parallel lines); see Supplementary Figure S7 online. (b) Relative expression of p53 gene targets. Quantitative PCR analysis of selected p53
targets in A375 cells infected with EV (grey bars) and D40p53V (black bars). p53-induced protein with a death domain (PIDD); poly(rC)-binding protein 4 (PCBP4);
apoptotic protease activating factor 1 (APAF1); Bcl-2–associated X protein (Bax); cyclin-dependent kinase 1 (p21); growth arrest and DNA-damage–inducible
protein a (GADD45A). *Po0.05. (c) Relative expression of p53 targets (PIDD, PCBP4, p21, and GADD45A) in D40p53-infected, g-irradiated A375 cells.
*Po0.05.
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fraction is most likely due to carryover from the nuclear
fraction, as indicated by the presence of Np62, a nuclear
protein. We could not detect any D40p53 in the cytoplasmic
fraction. To determine if D40p53 formed heterotetramers with
endogenous activated p53, we treated nuclear fractions of
D40p53-infected cells with glutaraldehyde to crosslink pro-
teins and looked for higher molecular weight oligomers by
western blot analysis as described previously (Powell et al.,
2008; Ungewitter and Scrable, 2010a). Using antibodies that
detect activated p53 (serine 15–phosphorylated p53), full-
length p53 (DO1 and CM1), and D40p53 (CM1), we found
bands at molecular weights corresponding to p53 tetramers,
p53/D40p53 tetramers, p53 dimers, and p53/D40p53 dimers
in glutaraldehyde-treated, but not -untreated, nuclear extracts
(Figure 5b; compare upper and lower panels). p53-specific
antibodies that recognize epitopes in the N terminus of the
protein (serine 15 and DO1) detected two bands, one
migrating above the 150 kDa marker in glutaraldehyde-treated
samples and the other at 50 kDa corresponding to p53
monomers.
Using CM1, which recognizes epitopes present in both p53
and D40p53, we found that all detectable D40p53 (migrating
above the 37 kDa marker in 0% glutaraldehyde samples) was
bound in tetramers with p53. These tetramers migrated above
the 150 kDa marker in glutaraldehyde-treated samples and
were detected by all three antibodies. We could detect p53
monomers but no D40p53 monomers in glutaraldehyde-
treated samples. A band migrating at 200 kDa above the
p53/D40p53 tetramer band (best visualized with CM1 in NI
and EV controls) indicated the apparent migration of endo-
genous p53 tetramers and was used as a reference point.
Likewise in the CM1 lanes, a band at approximately 100 kDa
in control lanes was used as a reference point for endogenous
p53 dimers. The band migrating below 100 kDa in the
D40p53V lane, therefore, must correspond to p53/D40p53
dimers. From these data, it is clear that D40p53 oligomerizes
with full-length p53 and, more importantly, forms tetramers
with activated p53 in the nucleus. This suggested a mole-
cular model by which the presence of D40p53 might
affect the expression of p53 target genes (identified by PCR
array and quantitative reverse transcriptase in real time
analysis) by modifying the ability of activated tetramers to
bind DNA.
D40p53 increases promoter occupancy of PIDD and p21
p53 isoforms, including D40p53, have been shown to mod-
ulate promoter occupancy of p53 gene targets by full-length
p53, a known transcription factor, and subsequently alter the
expression of downstream targets (Mills, 2005; Bourdon et al.,
2005a; Ungewitter and Scrable, 2010a). We hypothesized that
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Figure 5. D40p53 oligomerizes with endogenous activated p53 in the nucleus and increases promoter occupancy of PIDD and p21. (a) Nuclear and cytoplasmic
fractions of A375 cells infected with D40p53V. Nucleoporin 62 (Np62) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as nuclear
and cytoplasmic markers, respectively. (b) Higher order oligomers in A375 melanoma cells infected with D40p53V. Nuclear fractions of cells infected were
treated with glutaraldehyde (0.1%). p53 promoter occupancy at PIDD (c) and p21 (d) promoters. p53 antibodies were used to immunoprecipitate p53,
D40p53, and activated p53 from D40p53V-infected A375 cells for chromatin immunoprecipitation (ChIP) analysis (see Supplementary Figure S8 online). *Po0.05;
***Po0.001. (e) A model for how D40p53 alters cell fate. Endogenous p53 can be activated and directed by D40p53 to favor apoptosis over cell cycle arrest
(even with g-irradiation) in tumor cells. Our results are consistent with a role for D40p53 in the reactivation of p53-dependent tumor suppression.
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the increase in PIDD and decrease in p21 transcript levels
could be due to altered promoter occupancy by D40p53/p53
complexes. We tested this hypothesis by infecting A375
melanoma cells with either EV or D40p53V and used chro-
matin immunoprecipitation assays to determine promoter
occupancy at the LRDD and CDKN1A genes encoding
PIDD and p21, respectively. p53 was immunoprecipitated
from chromatin complexes using serine 15–phosphorylated
p53, pAb421, and 9282 antibodies. Rabbit IgG was used as a
control. At the PIDD promoter (Figure 5c), immunoprecipitat-
ing polyclonal p53 antibody 9282 revealed significantly
increased occupancy in D40p53-infected cells compared with
cells infected with the empty virus. Similarly, analysis of p21
promoter occupancy demonstrated a significant increase in
p53 molecules bound in the presence of D40p53V compared
to EV with p53 antibodies pAb421 (Figure 5d) and 9282
(Supplementary Figure S8 online). We did not find a significant
difference in promoter occupancy using the serine 15–
phosphorylated p53 antibody (Supplementary Figure S8 online).
In summary, we found that exogenous D40p53 increases
p53-dependent cell death by apoptosis in both cancer and
normal cells without altering cell cycle arrest. Consistent with
previous studies, g-irradiation did not induce cell cycle arrest
(Kaufmann et al., 2008), nor did it change the fraction of
dead cells. These data suggest that the decision to undergo
apoptosis is favored in the presence of D40p53 and cannot be
amended by exogenous stimuli such as g-irradiation. D40p53
increased the levels of endogenous, activated (serine
15–phosphorylated) p53 in A375 melanoma cells, which
could be enhanced by proteotoxic agents, such as cyclohex-
imide. Increased levels of endogenous p53 were not due to
phosphorylation by ATM/ATR as seen with g-irradiation.
D40p53 increased transcript levels of apoptotic targets, such
as PIDD, while suppressing the expression of cell cycle arrest
genes, such as p21. We found that D40p53 formed nuclear
heterotetramers with activated p53 and increased promoter
occupancy at both PIDD and p21 genes.
DISCUSSION
D40p53 is an isoform of p53 that is normally expressed only
during embryogenesis and in the stem cell compartment of
adult tissues (Medrano et al., 2009a; Ungewitter and Scrable,
2010b). Recently, we have also identified D40p53 as the only
consistently expressed p53 isoform in glioblastoma multiforme
(Takahashi et al., 2012), the most common brain tumor in
adults. To gain insight into the role of D40p53 in cancer, we
utilized a lentiviral system to overexpress D40p53 in tumors,
such as melanoma, and normal counterparts (melanocytes)
with or without functional p53. We chose an overexpression
model to parallel the p53 expression profiles previously
described in glioblastoma multiforme (Takahashi et al.,
2012). Our results are summarized in the model presented
in Figure 5e. We found that D40p53 shifted melanoma cell
fate in a p53-dependent manner to favor apoptosis over cell
cycle arrest, even in the presence of g-irradiation, a known
inducer of DNA damage and cell cycle arrest. D40p53
increased endogenous, activated p53 levels in melanoma
cells and increased the expression of downstream p53 targets
such as PIDD and suppressed others such as p21. D40P53
formed nuclear tetramers with endogenous, serine 15–
phosphorylated p53 and directly altered promoter occupancy
of PIDD and p21. Endogenous p53 phosphorylation by
D40p53 was dependent on proteotoxic and not genotoxic
damage, which led to significant levels of cell death. Our
results are consistent with a role for D40p53 in the reactivation
of p53-dependent tumor suppression.
Although p53 is the most frequently inactivated tumor
suppressor in human tumors, certain types of cancer, such
as melanoma, have relatively few TP53 mutations (Albino
et al., 1994; Montano et al., 1994; Weiss et al., 1995; Zerp
et al., 1999; Soto et al., 2005; Gwosdz et al., 2006; Li et al.,
2006). Despite high levels of wild-type protein expression,
studies have showed that p53 fails to execute downstream
functions such as cell cycle arrest and apoptosis in melanoma
primarily due to a failure in transactivating target genes
(Avery-Kiejda et al., 2011; Houben et al., 2011; Knopf
et al., 2011). Consequently, there have been a number of
studies that have focused on the idea of reactivating or
‘rescuing’ p53 function in cells with wild-type TP53 alleles
by introducing exogenous p53 (Kichina et al., 2003; Lane
et al., 2010) or by inhibiting Mdm, which has been found to
be overexpressed in melanomas (Danovi et al., 2004;
Muthusamy et al., 2006; Terzian et al., 2010; Gembarska
et al., 2012; Ji et al., 2012). Our results reveal a way in which
endogenous p53 can be activated and directed to increase
apoptosis in tumor cells. Validation of these results using
in vivo tumor models would be necessary to determine any
therapeutic utility of these findings.
MATERIALS AND METHODS
Lentiviral vectors and transduction
A375 melanoma cells (ATCC, Manassas, VA) and melanocytes (Life
Technologies, Grand Island, NY) were cultured according to the
manufacturer’s protocols. Primary glioblastoma cells and mouse
embryonic fibroblasts were cultured as described previously (Maier
et al., 2004b; Carlson et al., 2011). The D40p53 fragment was PCR
amplified and cloned into the pSIN construct (gift of Dr Yasuhiro
Ikeda, Mayo Clinic, Rochester, MN) and lentivirus produced as
described previously (Demaison et al., 2002). Transduction
efficiency 495% (based on GFP fluorescence) was achieved in all
infected cell types before carrying out downstream assays (approxi-
mately 5 days after infection for cancer cells and 10 days for non-
transformed cells).
Western blot analysis
Western blot analyses was carried out as described previously
(Ungewitter and Scrable, 2010b). p53 antibody includes: DO1 and
HR231 (Santa Cruz Technologies, Santa Cruz, CA), pAb421 and
pAb1801 (Calbiochem/EMD Chemicals, Gibbstown, NJ), phospho-
p53 (ser15) (Cell Signaling, Danvers, MA), CM1 (Vector Labs,
Burlingame, CA), and GAPDH (Ambion, Foster City, CA). PARP I
antibodies (Promega, Madison, WI) (Budihardjo et al., 1998). Serine
15 phosphorylation kinase and phosphatase antibodies used were as
follows: p-AMPKa, p-mTOR, p-RSK2, p70 S6K, CDK5, CDC25A (Cell
Signaling); cyclin B1 (Cell Signaling); and Np62 (BD Transduction
Laboratories, San Jose, CA).
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ATM/ATR inhibition and cycloheximide treatment
Infected A375 cells were treated with ATM/ATR inhibitor, CGK733
(10mM), or vehicle for approximately 60 hours and harvested for
western blot analysis.
Infected cells were treated with cycloheximide (100mg ml 1) or
vehicle and harvested at 1, 2, 3, 6, and 12 hours.
Subcellular fractionation
Infected A375 cells were harvested for nuclear and cytoplasmic
fractionation using the Qproteome Cell Compartment Kit (Qiagen,
Germantown, MD). For tetramer detection, nuclear fractions were
treated with 0.1% glutaraldehyde and analyzed as described pre-
viously (Ungewitter and Scrable, 2010b).
Cell cycle and apoptosis assays
The fraction of dead cells was determined by ethidium homodimer
binding (Life Technologies, Grand Island, NY), percentage of
apoptotic cells by Annexin V: PE Apoptosis Detection Kit I (BD
Pharmingen, San Jose, CA), and cell cycle profiles by propidium
iodide staining. PARP I products were detected by western blot
analysis. Cells were g-irradiated with 7 Gy and harvested at 3, 6,
or 9 hours after irradiation. Flow data were analyzed with
ModFit (Verity, Topsham, ME) and CellQuest (BD Biosciences,
San Jose, CA).
Quantitative PCR and chromatin immunoprecipitation assays
RNA harvested using a miRNeasy Mini Kit (Qiagen, Valencia, CA)
was reverse transcribed using a High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Grand Island, NY). iQ SYBR
Green Supermix was used for single gene PCR (Biorad, Hercules, CA).
The RT2 Profiler PCR array was used (SABiosciences, Valencia, CA)
for candidate p53 target discovery. Chromatin immunoprecipitation
analysis was carried out using Simple Chromatin Immunoprecipita-
tion Enzymatic Chromatin IP Kit (Magnetic Beads; Cell Signaling).
Immunoprecipitating antibodies used are as follows: serine 15–
phosphorylated p53, 9282, and rabbit IgG (Cell Signaling); pAb421
(Calbiochem/EMD Chemicals).
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